摘要
目的探讨肺癌患者血清转化生长因子-β1（TGF-β1）的水平变化和临床意义。方法采用酶联免疫吸附试验（ELISA）检测60例肺癌患者及30例健康者血清TGF-β1水平。结果肺癌组血清TGF-β1水平（30．073±13．790）ng／ml明显高于正常对照组（15．787±12．863）ng／ml（P〈0．01）；小细胞肺癌（SCLC）组血清TGF-β1水平（31．671±15．172）ng／ml与非小细胞肺癌（NSCLC）组的（28．766±12．635）ng／ml比较，差异无显著性（P〉0．05）；Ⅲ～Ⅳ期肺癌患者血清TGF-β1水平均明显高于Ⅰ～Ⅱ期肺癌患者（P〈0．01）。结论肺癌患者血清TGF-β1水平显著高于健康对照组，与肺癌病理类型无关，随TNM分期进展而升高，TGF-β1可能是肺癌的一种血清肿瘤标志物，并可作为病情监测指标。
Objective To explore the change in serum transforming growth factor -β1 （ TGF -β1 ） level in patients with lung cancer and to analyze its clinical significance. Methods The serum level of TGF -β1 was measured by enzyme - linked immunosorbent assay（ELISA） in 60 patients with lung cancer and 30 healthy control subjects. Results The serum level of TGF -β1 in patients with lung cancer（ 30. 073 ±13. 790 ng/ml） was significantly higher than that in normal subjects（ 15. 787 ±12. 863 ng/ml） （ P 〈0.01 ）. There was no significant difference in serum level ofTGF -β1 between small cell lung cancer（SCLC） （31. 671 ± 15. 172 ng/ml） and non - small cell lung cancer（NSCLC） （28. 766 ±12. 635 ng/ml） （ P 〉 0.05 ）. The serum level of TGF -β1 was significantly higher in patients with stage Ⅲ～Ⅳ lung cancer compared with that in stage Ⅰ～Ⅱlung cancer（ P 〈 0.01 ）. Conclusion The serum level of TGF -β1 in patients with lung cancer is significantly higher than that in normal subjects. It shows no relation to pathological types. But it raises with the increasing of TNM stages. The serum TGF -β1 may be a serum tumor marker and served as an useful indicator in the assessment of clinical stage.
出处
《临床和实验医学杂志》
2009年第9期11-12,共2页
Journal of Clinical and Experimental Medicine
